BIO-RAD LABORATORIES, INC. (NYSE:BIO) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM 5.07
|
Submission of Matters to a Vote of Security Holders.
|
of Stockholders on April 25, 2017. The matters voted upon at the
meeting and the results of those votes are set forth below.
|
1. Each of the nominated directors was elected and
received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows: |
|||||||
|
|
|
|
|
|
|
||
|
|
Class of
|
|
|
|
|
||
|
|
Common Stock
|
Votes
|
Votes
|
Votes
|
Broker
|
||
|
to Elect
|
For
|
Against
|
Abstaining
|
Non-Votes
|
|||
|
|
|
|
|
|
|
||
|
Melinda Litherland
|
Class A
|
19,962,061
|
345,415
|
3,151
|
2,064,610
|
||
|
Arnold A. Pinkston
|
Class A
|
19,963,761
|
343,155
|
3,711
|
2,064,610
|
||
|
Jeffrey L. Edwards
|
Class B
|
4,930,264
|
115,341
|
||||
|
Gregory K. Hinckley
|
Class B
|
4,930,178
|
–
|
115,341
|
|||
|
Alice N. Schwartz
|
Class B
|
4,923,164
|
7,649
|
–
|
115,341
|
||
|
Norman Schwartz
|
Class B
|
4,922,965
|
7,848
|
–
|
115,341
|
||
|
|
|||||||
|
|
|||||||
|
2. The proposal to ratify the selection of KPMG LLP as
the Companys independent auditors for the fiscal year ending December 31, 2017 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: |
|||||||
|
|
|||||||
|
Votes
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstaining
|
Non-Votes
|
||||
|
7,279,650
|
3,560
|
|
–
|
||||
|
|
|||||||
|
|
|||||||
|
3. The proposal to approve the Bio-Rad Laboratories, Inc.
2017 Incentive Award Plan was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: |
|||||||
|
|
|||||||
|
Votes
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstaining
|
Non-Votes
|
||||
|
6,030,772
|
927,471
|
3,633
|
321,802
|
||||
|
|
|
|
|
|
|
|
|
|
4. The proposal to approve an amendment to the Bio-Rad
Laboratories, Inc. 2011 Employee Stock Purchase Plan to increase the number of shares authorized thereunder by 700,000 was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: |
|||
|
|
|||
|
Votes
|
Votes
|
Votes
|
Broker
|
|
For
|
Against
|
Abstaining
|
Non-Votes
|
|
6,958,695
|
2,568
|
|
321,802
|
|
5. The non-binding advisory vote to approve executive
compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: |
|||
|
|
|||
|
Votes
|
Votes
|
Votes
|
Broker
|
|
For
|
Against
|
Abstaining
|
Non-Votes
|
|
6,894,740
|
63,091
|
4,045
|
321,802
|
|
|
||||
|
6. With respect to the non-binding advisory vote on the
frequency of future advisory votes to approve executive compensation, Three Years received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: |
||||
|
|
|
|
|
|
|
Votes
|
Votes
|
Votes
|
Votes
|
Broker
|
|
1 Year
|
2 Years
|
3 Years
|
Abstaining
|
Non-Votes
|
|
1,151,180
|
2,091
|
5,806,177
|
2,428
|
321,802
|
|
|
|
|
|
|
|
Consistent with the preferred frequency expressed by the
Company’s stockholders and the determination of the Companys Board of Directors, the Company has determined that it will hold a non-binding advisory vote to approve executive compensation every Three Years, until the next required non-binding advisory vote on the frequency of future non-binding advisory votes to approve executive compensation |
About BIO-RAD LABORATORIES, INC. (NYSE:BIO)
Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Company’s Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 products and services to a client base consisting of scientific research, healthcare, education and government customers around the world. BIO-RAD LABORATORIES, INC. (NYSE:BIO) Recent Trading Information
BIO-RAD LABORATORIES, INC. (NYSE:BIO) closed its last trading session up +0.94 at 219.20 with 291,165 shares trading hands.